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Diabetes and Increased Lipid Peroxidation are Associated with Systemic 
Inflammation Even in Well-Controlled Patients 
Abstract 
Background 
The effect of the interaction between type 2 diabetes and dyslipidemia on inflammation and lipid 
peroxidation (LPO) has not been assessed. 
Aim 
To investigate whether diabetes coupled with dyslipidemia alters oxidative metabolism leading to 
increased LPO products and inflammatory status. 
Methods 
100 patients were divided into four groups based upon diabetic and dyslipidemic status: poorly controlled 
diabetes with dyslipidemia (DM-PC/D), well-controlled diabetes with dyslipidemia (DM-WC/D), 
normoglycemic individuals with dyslipidemia (NG/D), and normoglycemic individuals without 
dyslipidemia (NG/ND). Plasma was evaluated for an LPO product (MDA), antioxidant levels and 
inflammatory cytokines. 
Results 
Diabetics presented significantly higher levels of LPO (p < 0.05) and the DM-PC/D had higher levels of 
proinflammatory cytokines and MDA in the plasma in comparison with normoglycemics (p < 0.05). 
Interestingly IL1-β, IL-6, and TNF-α in DM-WC/D were not statistically different from those in DM-PC/D. 
Normoglycemic individuals with dyslipidemia presented significantly increased levels of IL-6 and TNF-α 
when compared to normoglycemic without dyslipidemia (p < 0.05). MDA levels were also positively 
correlated with the presence of DM complications (r = 0.42, p < 0.01). 
Conclusions 
These findings show that dyslipidemia is associated with an increased inflammatory status, even in well-
controlled diabetics and in normoglycemics. Our results suggest that lipid metabolism and peroxidation 
are important for the development of inflammation, which is elevated in several complications associated 
with diabetes. 
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Abstract
Background—The effect of the interaction between type 2 diabetes and dyslipidemia on 
inflammation and lipid peroxidation (LPO) has not been assessed.
Aim—To investigate whether diabetes coupled with dyslipidemia alters oxidative metabolism 
leading to increased LPO products and inflammatory status.
Methods—100 patients were divided into four groups based upon diabetic and dyslipidemic 
status: poorly controlled diabetes with dyslipidemia (DM-PC/D), well-controlled diabetes with 
dyslipidemia (DM-WC/D), normoglycemic individuals with dyslipidemia (NG/D), and 
normoglycemic individuals without dyslipidemia (NG/ND). Plasma was evaluated for an LPO 
product (MDA), antioxidant levels and inflammatory cytokines.
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Results—Diabetics presented significantly higher levels of LPO (p < 0.05) and the DM-PC/D 
had higher levels of proinflammatory cytokines and MDA in the plasma in comparison with 
normoglycemics (p < 0.05). Interestingly IL1-β, IL-6, and TNF-α in DM-WC/D were not 
statistically different from those in DM-PC/D. Normoglycemic individuals with dyslipidemia 
presented significantly increased levels of IL-6 and TNF-α when compared to normoglycemic 
without dyslipidemia (p < 0.05). MDA levels were also positively correlated with the presence of 
DM complications (r = 0.42, p < 0.01).
Conclusions—These findings show that dyslipidemia is associated with an increased 
inflammatory status, even in well-controlled diabetics and in normoglycemics. Our results suggest 
that lipid metabolism and peroxidation are important for the development of inflammation, which 
is elevated in several complications associated with diabetes.
Keywords
Lipid peroxidation; Diabetes mellitus type 2; Cytokines; Dyslipidemia; Inflammation
1. Introduction
Diabetes is a group of metabolic diseases that leads to impaired wound healing (Goova et al., 
2001), higher susceptibility to infections (Hirsch et al., 2008), atherosclerosis (Halliwell, 
2000), micro- and macrovascular alterations (Ahmed, 2005; Mooradian, 2009; Velazquez, 
Winocour, Kesteven, Alberti, & Laker, 1991) even in diabetic patients with optimized 
glycaemic control (Chello et al., 2009). Inflammation is an underlying cause of several co-
morbidities associated with poorly controlled diabetes (Mirza et al., 2012) and several 
studies have demonstrated high levels of circulating inflammatory cytokines such as 
interleukin-6 and tumor necrosis factor α (TNF-α) (Mirza et al., 2012; Pickup, Chusney, 
Thomas, & Burt, 2000; Rytter et al., 2009; Vinik, 2005; Wisse, 2004) in type 2 diabetic 
patients.
Several mechanisms can contribute to the systemic hyperinflammatory status in diabetes, 
including dyslipidemia that modulates the function and activity of myeloid cells, and the 
increase of oxidative metabolism with enhanced production of reactive oxygen species 
(ROS) (Millar, Phan, & Tibbles, 2007). As a defense mechanism cells produce antioxidants 
(AOs) that prevent or limit oxidative tissue injury (Chapple & Matthews, 2007; Stosic-
Grujicic, Miljkovic, Cvetkovic, Maksimovic-Ivanic, & Trajkovic, 2004). Overproduction of 
ROS may result in an imbalance between ROS and AOS leading to oxidative stress and 
damage (Chapple & Matthews, 2007; Niedowicz & Daleke, 2005) that can contribute to 
injury of the host tissue by several mechanisms, including DNA damage, peroxidation of 
lipid membranes, oxidation of enzymes and stimulation of proinflammatory cytokines 
(Devaraj, Venugopal, Singh, & Jialal, 2005; Li, Huang, & Shen, 2014).
In spite of the biological rationale, there is paucity of information on the relationship 
between metabolic control in diabetes mellitus and the status of lipid metabolism 
(dyslipidemia), lipid peroxidation and antioxidant capacity as modulators of systemic 
inflammation in the same individual. The aim of this study is to determine whether type 2 
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diabetes, dyslipidemia and increased lipid peroxidation are specifically associated with 
aggravated systemic inflammation.
2. Materials and methods
2.1. Subjects
The present cross-sectional study, approved by the Human Research Ethics Committee of 
the School of Dentistry at Araraquara (UNESP–Univ. Estadual Paulista, Araraquara, Brazil; 
Protocol number 50/06), was conducted according to the ethical principles of the 
Declaration of Helsinki. Data collection was carried out between May 2009 and November 
2010. All volunteers were informed about the aims and methods of this study, and they 
provided their written consent to participate.
Patients with type 2 diabetes mellitus (T2DM) were recruited from local outpatient diabetic 
clinics, regional community hospitals, and physicians' offices. Normoglycemic individuals 
were consecutively selected from the list of patients who voluntarily sought dental treatment 
at the School of Dentistry at Araraquara, Univ. Estadual Paulista (UNESP), Brazil, at the 
same time as the DM2 group.
A simple questionnaire was applied initially to all subjects to identify the patients that were 
eligible to be enrolled in the study, considering the inclusion/exclusion criteria. All study 
participants ranged in age from 35 to 60 years and had similar socio-economic level. None 
of the patients were pregnant or were current or former smokers. Patients taking antibiotic, 
nonsteroidal anti-inflammatory, hormones or hypolipidemic drugs such as statins or fibrates, 
were excluded from the study. Particular care was taken to exclude subjects with history of 
anemia and diseases known to influence lipoprotein metabolism, such as hypothyroidism.
A power analysis based on a pilot study determined that at least 25 patients in each group 
would be sufficient to detect a 3-unit difference in MDA levels or a 2.4-unit difference in an 
inflammatory cytokine with 90% power and 95% confidence interval. The population was 
divided into four groups based upon diabetic and dyslipidemic status: poorly controlled 
diabetics with dyslipidemia (DM-PC/D), well-controlled diabetics with dyslipidemia (DM-
WC/D), normoglycemic individuals with dyslipidemia (NG/D), and healthy individuals 
(NG/ND). Post hoc power calculation (at the 95% significance level, p = 0.05) showed that 
all comparisons had a power > 0.8 except for hsCRP (0.56), triglycerides (0.65), and 
abdominal circumference (0.18).
2.2. Clinical record and physical evaluation
After enrolling in the study, all participants answered a face-to-face structured questionnaire 
about socio-demographic data, personal and family medical history, and use of medications. 
A trained examiner collected information from diabetic patients regarding time since 
diabetes onset, medication used to control glucose, and the presence of complications 
associated with diabetes. Subjects completed a physical examination including 
anthropometric data such as abdominal circumference (cm), hip (cm), waist (cm), height 
(m), weight (kg) and body mass index (BMI).
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2.3. Laboratory measurements: metabolic control and lipoprotein profile
Blood samples were collected after a 12-h overnight fast to evaluate blood cell counts (white 
and red series), fasting plasma glucose (mg/dl) by modified Bondar and Mead method, 
glycated hemoglobin (HbA1c) by enzymatic immunoturbidimetry, insulin levels by the 
chemiluminescence immunoassay, high-sensitivity C-reactive protein by the nephelomeric 
method and lipid profile (total cholesterol (TC), triglycerides (TGs), and HDL) by enzymatic 
methods. LDL was determined by the Friedewald formula. The same laboratory performed 
all analyses.
To avoid the inclusion of individuals with transitory dyslipidemia, the cutoff points used 
were the highest values according to the National Cholesterol Educational Program (NCEP) 
Adult Treatment III (ATP III) (NCEP, 2002): TC ≥ 240 mg/dl, LDL ≥ 160 mg/dl, HDL ≤ 40 
mg/dl, and TGs ≥ 200 mg/dl. Metabolic control was considered as inadequate when HbA1c 
≥ 8.5% and these patients were included in the DM-PC/D Group (Diabetes Poorly 
Controlled with Dyslipidemia). When HbA1c < 7.0% the metabolic control was considered 
as adequate and these patients were included in the DM-WC/D (Diabetes Well-controlled 
with Dyslipidemia). The homeostasis model assessment of insulin resistance (HOMA IR) 
was calculated by the formula: fasting insulin concentration (µU/ml) × fasting glucose 
concentration (mmol/L) divided by 22.5 (Matthews et al., 1985).
2.4. Sample collection
Blood samples were collected in tubes with EDTA centrifuged at 3000 × g for 10 min at 
4 °C, promptly aliquoted and stored at −80 °C until the analyses. The following assays were 
performed by professionals unaware of the experimental groups.
2.5. Analysis of cytokines in plasma
Eleven cytokines (interleukin-1β [IL-1β], IL-2, -4, -5, -6, -7, -8, -10, -12 (p70) and -13 and 
tumor necrosis factor-alpha [TNF-α]) were measured in plasma samples by multiplex beads 
(Bio-Plex system, Bio-Rad Laboratories, Hercules, CA, USA), following the manufacturer's 
instructions.
2.6. Lipid peroxidation and antioxidant assays
2.6.1. MDA assay—The assessment of MDA in plasma was determined by HPLC 
(Shimadzu, Tokyo, Japan) with a reverse-phase HPLC column (C18; 4.6 × 150 mm) 
(Phenomenex, Torrance, CA, USA) and compared with MDA standard curves. Plasma 
samples were prepared as described previously (Hong, Yeh, Chang, & Hu, 2000).
2.6.2. Antioxidant assay—The levels of total antioxidant capacity of plasma were 
evaluated with a commercially available colorimetric kit (Cayman Chemical Company®, 
Ann Arbor, MI, USA) following the manufacturer's instructions. The absorbance at 750 nm 
was measured by spectrophotometry using a plate reader and the results were expressed as 
Trolox (mM).
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2.7. Statistical analysis
The distribution and normality of the variables were evaluated by the D'Agostino–Pearson 
test. Subsequently, the general characteristics of each group were described as mean and 
standard deviation (SD); the cytokines expression in plasma were expressed as median 
(25%/75% quartiles) in Table 1 and as mean and standard deviation (SD) in Fig. 2. The 
differences between the groups for parametric data were evaluated by ANOVA followed by 
Bonferroni's post-test, and non-parametric data were evaluated by the Kruskall–Wallis test, 
followed by Dunn's post-test. Correlations were analyzed by the Pearson rank test adjusting 
for age, gender, and BMI. To determine the influence of lipid peroxidation and diabetic 
status on the expression of plasma cytokines, separate multivariable logistic and linear 
regression models were built for each independent variable. Variables found to be associated 
with the independent and dependent variables, and thus possible confounding factors, were 
included in the models. Moreover, regardless of their statistical significance, all variables 
known to have biologic linkage with the outcomes were retained. Based on previous studies 
(Carey et al., 2004; Fentoglu et al., 2009), correlation and regression models were adjusted 
for age, gender, BMI, and triglycerides, considered important as possible confounders in 
establishing the relationship among the variables of interest. The significance level was set at 
α = 0.05. All analyses were carried out with SPSS software, IBM version 19.
3. Results
3.1. Sample population
The general characteristics of the sample population are shown in Table 1. From the 
screened patients, 100 were identified as meeting the study inclusion criteria; of these, 25 
patients were assigned to one of four different groups. There was no statistically significant 
difference among the participants with respect to gender, age and socioeconomic status. In 
relation to physical evaluation, all individuals were overweight and the diabetic groups were 
obese and presented higher values of BMI (p < 0.05), waist/hip proportion and abdominal 
circumference. The groups with diabetes had significantly increased levels of fasting 
glucose, HbA1c, and insulin resistance compared with normoglycemic patients. Based on 
ATP III (NCEP, 2002) definition of dyslipidemia, groups DM-PC/D, DM-WC/D and NG/D 
were dyslipidemic presenting increased levels of total cholesterol, LDL cholesterol, and 
triglycerides compared with group NG/ND (healthy individuals) (p < 0.05). The evaluation 
of total and differential counting of cells (white and red series) showed a statistical 
difference between poorly controlled diabetic/dyslipidemic patients regarding white blood 
cells (total leucocytes, neutrophils and lymphocytes) and healthy individuals (p < 0.05). 
There was no difference in time since diabetes onset (years) between poorly controlled/
dyslipidemic (6.5 ± 4.5) and well-controlled/dyslipidemic diabetics (5.5 ± 7.1). Regarding 
diabetic complications, 60% of the poorly controlled diabetics and 40% of the well-
controlled diabetics presented at least one complication related to type 2 DM. This 
difference was significant (p < 0.05), with the most common complication being retinopathy, 
followed by nephropathy. A total of 17 patients from DM-PC/D were treated with oral 
antidiabetic agents, 1 patient was treated with insulin therapy, and 7 were treated with the 
combination of insulin and antidiabetic agents. From the group DM-WC/D, 12 patients were 
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treated with oral antidiabetic agents, 1 was treated with insulin therapy, 4 were treated with 
the combination of insulin and antidiabetic agents and 8 were treated with no drug therapy.
3.2. Lipid peroxidation levels
3.2.1. Plasma malondialdehyde (MDA)—Plasma MDA levels were slightly increased 
in all dyslipidemic patients, regardless of their glycemic status. The highest level of plasma 
MDA was observed in poorly controlled diabetics with dyslipidemia who had about 2.9 
times higher MDA levels when compared with those in the normoglycemic groups (p < 
0.05) and approximately 1.6 times higher MDA levels when compared with well-controlled 
diabetics with dyslipidemia (p < 0.05) (Fig. 1). Well-controlled diabetics with dyslipidemia 
(DM-WC/D) presented significantly increased levels of MDA (p < 0.05) when compared 
with those in the normoglycemic groups (NG/D and NG/ND). Normoglycemic individuals 
with dyslipidemia had no increase in MDA levels compared to normoglycemic individuals 
without dyslipidemia (p > 0.05) indicating that the presence of hyperglycemia played a 
critical role in the increased MDA.
3.2.2. Antioxidant assay results—The levels of total antioxidant capacity of plasma 
were expressed as mean (± SD) and showed increased values in the groups without type 2 
diabetes (NG/ND: 0.69 (± 0.18) and NG/D: 0.66 (± 0.21)) and in the well-controlled 
diabetics (DM-WC/D: 0.66 (± 0.18)). The group with poorly controlled diabetes with 
dyslipidemia (DM-PC/D), presented the lowest levels of plasma antioxidant capacity. 
However this difference was not significantly different between any of the groups (p > 0.05) 
(Table 1).
3.3. Systemic inflammation
Overall, the expression of proinflammatory cytokines gradually increased from NG/ND, 
NG/D, DM-WC/D, DM-PC/D (p < 0.05) indicating that diabetes significantly enhances the 
systemic level of inflammation. The cytokines’ expression in plasma were expressed as 
median (25%/75% quartiles) in Table 1 and as mean and standard deviation (SD) in Fig. 2. 
The cytokines that are typically considered adipokines such as IL-6 and TNF-α were also 
significantly increased in the groups with dyslipidemia in comparison with the group 
without dyslipidemia.
3.4. Statistical analysis
3.4.1. Correlation analysis—Table 2 shows the adjusted correlation among diabetes 
status, lipoprotein profile, anthropometric and lipid peroxidation markers, and plasma 
cytokine expression taking into account the effect of age, gender and BMI. There was a wide 
range of moderate positive correlations observed among diabetic status, lipid peroxidation 
markers and expression of proinflammatory cytokines. Among the most significant 
correlations were IL1-β with the following: fasting glucose (0.48), HbA1c (0.40) and MDA 
(0.50); all of which were significant (p < 0.0001). Moderate positive significant correlation 
was also observed among TNF-α and: fasting glucose (0.50), HbA1c (0.50), triglycerides 
(0.35) and MDA (0.44) (p < 0.0001). Diabetes was significantly associated with lipid 
peroxidation markers, and there was a strong positive correlation observed between MDA 
and HbA1c (r = 0.643, p < 0.0001), suggesting that poor metabolic control is associated with 
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higher expression of MDA. The presence of complications related to type 2 diabetes mellitus 
(T2DM), with the most common complication being retinopathy, followed by nephropathy 
was positively correlated with HbA1c levels (r = 0.45, p < 0.01), MDA (r = 0.42, p < 0.01), 
diabetes duration (r = 0.47, p < 0.001) and TNF-α (r = 0.35, p < 0.05). Significant positive 
correlations (p < 0.05) were observed between insulin resistance (HOMA IR) and IL-6 
(0.21), TNF-α (0.25) and between triglycerides and IL-1 (0.20), IL-6 (0.24) and TNF-α 
(0.35). Besides, a significant positive correlation was observed between adipocytokines and 
lipoprotein profile, such as IL-6 and triglycerides (0.24), IL-6 and total cholesterol (0.25) 
and TNF-α and triglycerides (0.35).
The possible linkage among inflammation, diabetes, and lipid peroxidation is demonstrated 
by a multiple regression analysis using separate models for independent variables. Lipid 
peroxidation markers and diabetic status were directly related to the expression of 
inflammatory cytokines, especially IL-1β (β = 0.40) and TNF-α (β = 0.50). IL-6 was 
significantly related to lipoprotein profile rather than diabetic or inflammatory status (Table 
3).
3.4.2. Regression analysis—To further define the influence of lipid peroxidation, poor 
metabolic control and lipoprotein profile on increased levels of systemic inflammation, a 
logistic regression was performed taking into account the effects of age, gender and BMI. 
There was an approximate 3.2-, 2.0-, 1.9- and 2.6-fold increase in the odds of having 
elevated levels of IL-1β, IL-6, IL-8, and TNF-α, respectively, among those patients who 
have higher plasmatic levels of MDA (p < 0.05). In addition, increased levels of HbA1c were 
associated with a ~ 1.5-fold increase in the odds ratio of high of IL-1β, IL-8, and TNF-α (p 
< 0.05). In respect to lipoprotein profile and the relationship with increased expression of 
inflammatory cytokines, only elevated triglycerides were associated with a ~ 1.5-fold 
increase in the odds of high of IL-1β, IL-6, TNF-α and IL-4 (p < 0.05) and abdominal 
circumference increased the odds of having elevated IL-8 and TNF-α (Table 4).
4. Discussion
In the present study we investigated whether type 2 diabetes mellitus (T2DM) coupled with 
dyslipidemia was associated with altered oxidative metabolism and increased lipid 
peroxidation and whether they were linked to greater systemic inflammation. Our results 
indicate that diabetes associated with dyslipidemia, even in well-controlled patients, was 
associated with increased lipid peroxidation. Furthermore, dyslipidemia and increased lipid 
peroxidation were strongly correlated with higher levels of systemic inflammation.
Previous studies evaluated cytokines in plasma of patients with diabetes (Arnalich et al., 
2000; Mirza et al., 2012; Pickup et al., 2000) and their association with diabetic 
complications (Liu et al., 2010; Ridker et al., 2000). However to the best of our knowledge, 
this is the first study to establish a relationship between type 2 diabetes mellitus (T2DM) and 
dyslipidemia and their impact on lipid peroxidation levels and systemic inflammation. 
Elevated proinflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α) were detected in diabetic 
patients and the presence of complications, such as retinopathy and nephropathy, was 
positively associated with increased levels of TNF-α. The anti-inflammatory cytokine IL-4 
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was also elevated in diabetic patients. Interestingly, the levels of proinflammatory cytokines 
(IL1-β, Il-6, TNF-α) in well-controlled diabetics with dyslipidemia were not statistically 
different from those of poorly controlled diabetics with dyslipidemia. These findings suggest 
that dyslipidemia might be one of the driving forces for elevated systemic inflammation even 
in well-controlled diabetics.
It is known that obesity promotes dyslipidemia and may impact insulin action via additional 
pathways, including the release of leptin, IL-6 and TNF-α (Vinik, 2005). In the present 
study, diabetic individuals were considered obese if they had BMI > 30 and a large waist 
circumference compared to healthy patients. Abdominal circumference statistically 
increased the odds of having elevated IL-8 and TNF-α. Besides, patients with type 2 
diabetes had an increased insulin resistance index (HOMA IR) compared to healthy patients 
and significant associations were observed between insulin resistance (HOMA IR) and 
cytokines (IL-6 and TNF-α). This fact is in accordance with previous studies that 
demonstrated the association between insulin resistance and the increased expression of 
inflammatory cytokines (Vinik, 2005; Wisse, 2004).
The pathogenesis of diabetic dyslipidemia is not completely elucidated, although it is 
recognized that lipid abnormalities are a primary feature of metabolic syndrome and can 
precede the clinical manifestation of hyperglycemia (Davi et al., 2003; Ginsberg, 1991; 
Haffner, 2002; Kreisberg, 1998). It is important to note that even with the well-established 
effect of dyslipidemia on type 2 diabetes (Chisolm, Irwin, & Penn, 1992; Haffner, 2002; 
Krauss & Siri, 2004; Kreisberg, 1998) several studies with diabetic populations do not take 
into consideration the serum lipid characteristics of the population (Davi et al., 2003; 
Esposito et al., 2002; Liu et al., 2010; Pandey, Mishra, & Rizvi, 2010; Pickup et al., 2000) or 
the level of dyslipidemia (Cakatay, 2005; Esposito et al., 2002; Hussein et al., 2007; Mirza et 
al., 2012; Nakhjavani et al., 2010; Van Guilder, Hoetzer, Greiner, Stauffer, & Desouza, 
2006). In the present study we evaluated the lipid profile of the whole population and 
included in dyslipidemic groups only patients with values consistent with an established 
dyslipidemia (NCEP, 2002). There was an elevated inflammatory status in normoglycemic 
dyslipidemic individuals (NG/D). This group presented significantly increased levels of IL-6 
and TNF-α when compared to normoglycemic without dyslipidemia (NG/ND), suggesting 
that dyslipidemia itself can increase the release of proinflammatory cytokines. In addition, a 
positive correlation was observed between adipocytokines, IL-6 and TNF-α and 
triglycerides and total cholesterol.
A limitation of many studies evaluating diabetic individuals is the lack of attention 
concerning metabolic and dyslipidemic status, not separating the patients based on 
dyslipidemia and controlled/poorly controlled type 2 diabetes mellitus, based on recent and 
updated HbA1c levels (Cakatay, 2005; Gambino et al., 2004; Hussein et al., 2007; 
Kostolanska, Jakus, & Barak, 2009; Rytter et al., 2009). We analyzed the DM patients as 
separate groups based on the quality of metabolic control. As expected we observed a 
significant increase in lipid peroxidation and proinflammatory cytokines in poorly controlled 
diabetics when compared to the other groups, consistent with other reports (Chisolm et al., 
1992; Colas et al., 2010; Dennis et al., 2010; Gambino et al., 2004; Hussein et al., 2007; 
Mirza et al., 2012; Nishigaki, Hagihara, Tsunekawa, Maseki, & Yagi, 1981; Nishimura, 
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Iwamoto, & Soga, 2007; Sundaram et al., 1996). However, analysis of the data considering 
the metabolic status and lipid profile allowed us to observe novel findings related to the 
impact of dyslipidemia on the level of systemic inflammation in well-controlled diabetics.
Well-controlled diabetics are usually considered at a lower risk to develop cardiovascular 
disease and diabetic complications when compared to patients with inadequate metabolic 
control (American Diabetes, A, 2015; NCEP, 2002). For this reason lipid profile and levels 
of acute phase proteins are not usually evaluated in these patients. Interestingly, in the 
present study, well-controlled diabetics with dyslipidemia (DM-WC/D) showed significantly 
the highest levels of high sensitivity C-reactive protein. This unexpected finding could 
probably be due to the fact that this group also presented significantly increased measures of 
abdominal circumference (Hak et al., 1999; Lakka, Lakka, Salonen, Kaplan, & Salonen, 
2001; Mendall et al., 2000). However, in the present study the statistical analysis did not 
show significant correlation between C-reactive protein and abdominal circumference after 
the adjustment for age, gender and BMI. The DM-WC/D group also showed high levels of 
lipid peroxidation and proinflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α). Thus, the 
inflammatory and lipid peroxidation levels of the well-controlled diabetics were more 
similar to those of the poorly controlled diabetics and markedly higher than to those of the 
normoglycemic group with dyslipidemia. This shows the importance of better evaluation of 
these patients even if they are considerated well-controlled diabetics and also suggests that 
increased lipid peroxidation and systemic inflammation may represent a possible risk for the 
development of complications and imbalance in the metabolic control. In support to this 
possibility, other studies have also emphasized the hypothesis that lipid peroxidation 
contributes to the initiation and progression of diabetes (Giugliano, Ceriello, & Paolisso, 
1996; Van Dam et al., 1995) and that oxidative stress can be an important early event in the 
pathogenesis of complications secondary to diabetes (Sasaki & Inoguchi, 2012) and may 
indicate an underlying subclinical pathology despite the good metabolic control (Cakatay, 
2005). We add to these findings that lipid peroxidation is positively associated with 
complications related with type 2 diabetes and also with systemic inflammation, particularly 
IL-1β and TNF-α.
The cross-sectional design of the present study limited the interpretation of our findings. 
Thus, the temporal sequence showing whether diabetes coupled with dyslipidemia precedes 
the increased systemic inflammation or vice versa is not known. Nonetheless, the present 
study intended to assess the direction of the association as to whether diabetes coupled with 
dyslipidemia leads to increase in systemic inflammation. In an effort to minimize the 
influence of lifestyle behaviors and the effects of confounding factors, particular care was 
taken to use strict inclusion criteria, having subjects of similar socioeconomic level, age and 
gender-matched, who were not currently taking medication that could influence 
inflammatory and oxidative markers (i.e., statins). Nevertheless, our study suggests that 
increased lipid peroxidation aggravates systemic inflammation even in well-controlled 
diabetics and normoglycemic dyslipidemic patients.
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5. Conclusion
In conclusion, our study suggests that lipid peroxidation may represent an additive effect to 
the metabolic imbalance associated with type 2 diabetes, increased systemic inflammation 
and the development of diabetes-associated complications. In this sense, dyslipidemia may 
have a relevant impact on systemic inflammation via altered oxidative metabolism leading to 
increased lipid peroxidation even in well-controlled diabetics.
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Fig. 1. 
Lipid Peroxidation expression in plasma: Levels of MDA (µM). Data are presented as mean 
SD (**p < 0.0001 in relation to groups 2, 3 and 4; *p < 0.05 in relation to groups 3 and 4; 
ANOVA Test; α = 5%).
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Fig. 2. 
Cytokines’ expression in plasma (pg/ml). Data are presented as mean and standard deviation 
(SD) (**p < 0.0001 in relation to group 4; *p < 0.05 in relation to group 4; #p < 0.05 in 
relation to group 3; Kruskall–Wallis Test; α = 5%).
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Table 1
Characteristics of the sample: demographic, physical, laboratory, antioxidants and cytokines data.
DM-PC/D
(DM ≥ 8.5%/with 
dyslip)
DM-WC/D
(DM < 7.0%/with 
dyslip)
NG/D
(normoglycemic/with dyslip)
NG/ND
(normoglycemic/without dyslip)
Gender (F/M) 14/11 15/10 14/11 15/10
Age 47.8 (± 7.7) 50.3 (± 6.7) 49.1 (± 7.9) 45.6 (± 5.3)
BMI (m/kg2) 30.8 (± 4.1)# 30.9 (± 4.1)# 28.5 (± 4.0) 27.6 (± 6.9)
Abdominal circumference 103.7 (± 14.3) 107.9 (± 10.0)#,§ 98.2 (± 10.7) 98.1 (± 18.0)
Waist/hip ratio 1.0 (± 0.1) 1.0 (± 0.1) 0.9 (± 0.1) 0.9 (± 0.1)
Fasting glucose (mg/dL) 233.4 (± 76.6)†,‡ 137.7 (± 43.5)‡ 90.2 (± 6.1) 91.0 (± 7.5)
HbA1c (%) 10.7 (± 1.8)** 6.5 (± 0.7)§,# 5.5 (± 0.7) 5.2 (± 0.6)
Insulin (U/L) 17.7 (± 14.5)# 16.2 (± 7.8)# 12.5 (± 8.3) 12.1 (± 13.7)
HOMA IR Index 9.8 (± 8.5)‡ 5.4 (± 2.7)§,# 2.8 (± 1.8) 2.8 (± 3.4)
Total cholesterol (mg/dL) 244.0 (± 38.5)## 247.3 (± 44.3)## 244.8 (± 41.9)## 173.9 (± 18.4)
HDL cholesterol (mg/dL) 45.9 (± 9.8) 47.2 (± 10.6) 50.0 (± 11.3) 48.9 (± 13.4)
LDL cholesterol (mg/dL) 153.6 (± 39.0)## 150.8 (± 45.1)## 157.0 (± 43.2)## 105.5 (± 17.8)
Triglycerides (mg/dL) 218.1 (± 94.2)## 246.2 (± 108.4)## 189.1 (± 82.7)## 94.1 (± 37.8)
Hs C-Reactive Protein 
(mg/dL)
0.4 (± 0.3) 0.7 (± 0.5)# 0.4 (± 0.3) 0.4 (± 0.6)
White blood Cells (mm3) 7.403 (± 1.687)## 7.144 (± 1.932) 6.886 (± 1.814) 5.903 (± 1.503)
Red blood cells (× 106) 4.9 (± 0.4) 4.7 (± 0.5) 4.9 (± 0.4) 4.6 (± 0.5)
Antioxidants (mM) 0.60 (± 0.20) 0.66 (± 0.18) 0.66 (± 0.21) 0.69 (± 0.18)
IL-1β (pg/ml) 0.48 (0.39/0.82)§,## 0. (0.39/0.60)## 0.41 (0.32/0.45) 0.35 (0.29/0.38)
IL-2 (pg/ml) 0.39 (0.0/0.71) 0.39 (0.22/0.49) 0.26 (0.0/0.48) 0.33 (0.22/0.42)
IL-4 (pg/ml) 0.67 (0.44/1.0)# 0.42 (0.22/1.0) 0.44 (0.26/0.82) 0.37 (0.15/0.45)
IL-5 (pg/ml) 1.28 (1.17/1.64)# 1.36 (1.09/1.5) 1.2 (1.04/1.4) 1.14 (1.0/1.28)
IL-6 (pg/ml) 1.57 (1.27/2.04)# 1.57 (1.19/1.8)# 1.41 (1.2/1.8)# 1.01 (0.54/1.3)
IL-7 (pg/ml) 1.14 (1.01/1.36) 1.14 (1.0/1.4) 1.06 (0.9/1.4) 1.0 (0.85/1.2)
IL-8 (pg/ml) 2.54 (2.0/3.0)## 2.16 (1.84/2.82)# 2.25 (1.8/2.5) 1.88 (1.4/2.1)
IL-10 (pg/ml) 0.71 (0.6/0.8) 0.74 (0.6/1.0) 0.71 (0.63/0.82) 0.64 (0.6/0.7)
IL-12 (p70) (pg/ml) 0.99 (0.3/1.1) 0.90 (0.7/1.0) 0.90 (0.3/1.0) 0.90 (0.7/1.1)
IL-13 (pg/ml) 1.93 (1.3/2.9) 1.85 (1.2/2.5) 2.0 (1.4/2.9) 1.7 (1.3/2.5)
TNF-α (pg/ml) 5.68 (4.5/7.0)§,## 5.0 (4.0/6.2)## 4.56 (3.9/4.1)# 2.68 (1.5/4.2)
Data are presented as mean SD or median (25th/75th percentile).
#p < 0.05 in relation to group 4;
##p < 0.0001 in relation to group 4;
§p < 0.05 in relation to group 3;
†p < 0.05 in relation to group 2;
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‡p < 0.0001 in relation to groups 3 and 4;
**p < 0.0001 in relation to the other groups (Kruskal–Wallis Test; α = 5%).
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